Edgar Filling. Action Filamidocations inc. Form 50 Foc
Xenon Pharmaceuticals Inc. Form SC 13G/A March 29, 2018 UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
(Rule 13d-102)
INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT
TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED
PURSUANT TO RULE 13d-2(b)
(Amendment No. 6) ¹
Xenon Pharmaceuticals Inc. (Name of Issuer)
Common Shares, no par value per share (Title of Class of Securities)
98420N105 (CUSIP Number)
March 27, 2018 (Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)

The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, *see* the *Notes*).

1	NAME OF REPORTING PERSON		
		nology Value Fund,	
	L.P. CHECK TH	IE.	
	APPROPRI		
2	BOX IF A	(a)	
	MEMBER GROUP	OF A	
	GROOI	(b)	
3	SEC USE C	ONLY	
4	CITIZENSI ORGANIZA	HIP OR PLACE OF ATION	
	Delawar	re	
NUMBER OF	5	SOLE VOTING	
SHARES	J	POWER	
BENEFICIALLY	7	0 shares	
OWNED BY	6	SHARED VOTING POWER	
EACH REPORTING		1,108,474 ⁽¹⁾	
REI ORTING		SOLE	
PERSON WITH	7	DISPOSITIVE	
		POWER	
		0 shares	
		SHARED	
	8	DISPOSITIVE POWER	
		FOWER	
		1,108,474 ⁽¹⁾	
9	AGGREGATE AMOUNT BENEFICIALLY OWNED BY		
9		ORTING PERSON	
10	1,108,474 ⁽¹⁾ CHECK BOX IF THE AGGREGATE		
10			
	AMOUNT IN ROW (9) EXCLUDES		
	CERTAIN		

SHARES

PERCENT OF CLASS
11 REPRESENTED BY AMOUNT
IN ROW (9)

 $7.4\%^{(1)}$

12 TYPE OF REPORTING PERSON

PN

(1) Includes 772,006 shares of Common Stock currently issuable upon conversion of 772,006 shares of Series 1 Preferred (defined in Item 4). Excludes 565,994 shares of Common Stock underlying certain shares of Series 1 Preferred currently not convertible due to the Beneficial Ownership Limitation (defined in Item 4). As of the close of business on March 29, 2018, the Beneficial Ownership Limitation limits the aggregate conversion of Series 1 Preferred by the Reporting Persons to 772,006 out of the 2,868,000 shares of Common Stock underlying the Series 1 Preferred owned by the Reporting Persons in the aggregate.

1	NAME OF REPORTING PERSON		
2	Biotechn II, L.P. CHECK TH APPROPRIA BOX IF A MEMBER O GROUP	ATE (a)	
		(0)	
3	SEC USE O	NLY	
4	CITIZENSH ORGANIZA	IIP OR PLACE OF ATION	
	Delaware	2	
NI IMPED OF	5	SOLE VOTING	
NUMBER OF	3	POWER	
SHARES BENEFICIALLY	r	O altamas	
DENEFICIALL I		0 shares SHARED	
OWNED BY	6	VOTING POWER	
EACH		1 O WER	
REPORTING		216,694(1)	
DED CON WITH	7	SOLE	
PERSON WITH	7	DISPOSITIVE POWER	
		10,1121	
		0 shares	
	8	SHARED DISPOSITIVE	
	O	POWER	
	AGGREGA'	216,694 ⁽¹⁾ TE AMOUNT	
0		LLY OWNED	
9	BY EACH F	REPORTING	
	PERSON		
	216,694	1)	
10	CHECK BOX IF THE AGGREGATE		
	AMOUNT I (9) EXCLUI		
	マクルじんしたし1	JEO JEO	

CERTAIN

SHARES

PERCENT OF CLASS
REPRESENTED BY
AMOUNT IN ROW (9)

 $1.5\%^{(1)}$

12 TYPE OF REPORTING PERSON

PN

(1) Excludes 861,000 shares of Common Stock underlying certain shares of Series 1 Preferred currently not convertible due to the Beneficial Ownership Limitation. As of the close of business on March 29, 2018, the Beneficial Ownership Limitation limits the aggregate conversion of Series 1 Preferred by the Reporting Persons to 772,006 out of the 2,868,000 shares of Common Stock underlying the Series 1 Preferred owned by the Reporting Persons in the aggregate.

1	NAME OF REPORTING PERSON		
2		ATE (a)	
	GROUP		
		(b)	
3	SEC USE O	NLY	
4	CITIZENSH OF ORGAN	IIP OR PLACE IIZATION	
	Cayman	Islands	
NUMBER OF	5	SOLE VOTING POWER	
SHARES BENEFICIALLY	•	0 shares	
OWNED BY	6	SHARED VOTING POWER	
EACH REPORTING		59,464 ⁽¹⁾	
PERSON WITH	7	SOLE DISPOSITIVE POWER	
	8	0 shares SHARED DISPOSITIVE POWER	
9	BENEFICIA	59,464 ⁽¹⁾ TE AMOUNT ALLY OWNED REPORTING	
10	59,464 ⁽¹⁾ CHECK BO THE AGGR AMOUNT I	X IF EGATE	

(9) EXCLUDES CERTAIN SHARES

PERCENT OF CLASS
REPRESENTED BY
AMOUNT IN ROW (9)

Less than 1%⁽¹⁾
TYPE OF REPORTING
PERSON

PN

⁽¹⁾ Excludes 238,000 shares of Common Stock underlying certain shares of Series 1 Preferred currently not convertible due to the Beneficial Ownership Limitation. As of the close of business on March 29, 2018, the Beneficial Ownership Limitation limits the aggregate conversion of Series 1 Preferred by the Reporting Persons to 772,006 out of the 2,868,000 shares of Common Stock underlying the Series 1 Preferred owned by the Reporting Persons in the aggregate.

4

1	NAME OF REPORTING PERSON		
2	BVF Par CHECK TH APPROPRI BOX IF A MEMBER O GROUP	ATE (a)	
		(b)	
3	SEC USE O	NLY	
4	CITIZENSHIP OR PLACE OF ORGANIZATION		
	Cayman Islands		
NUMBER OF	5	SOLE VOTING	
	3	POWER	
SHARES BENEFICIALLY	7	0 shares	
DENEFICIALLI		SHARED	
OWNED BY	6	VOTING	
		POWER	
EACH		50.464(1)	
REPORTING		59,464 ⁽¹⁾ SOLE	
PERSON WITH	7	DISPOSITIVE POWER	
	8	0 shares SHARED DISPOSITIVE POWER	
9	BENEFICIA	59,464 ⁽¹⁾ TE AMOUNT ALLY OWNED REPORTING	
10	59,464 ⁽¹⁾ CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES		

CERTAIN SHARES

PERCENT OF CLASS
REPRESENTED BY
AMOUNT IN ROW (9)

Less than 1%⁽¹⁾

12 TYPE OF REPORTING

PERSON

CO

⁽¹⁾ Excludes 238,000 shares of Common Stock underlying certain shares of Series 1 Preferred currently not convertible due to the Beneficial Ownership Limitation. As of the close of business on March 29, 2018, the Beneficial Ownership Limitation limits the aggregate conversion of Series 1 Preferred by the Reporting Persons to 772,006 out of the 2,868,000 shares of Common Stock underlying the Series 1 Preferred owned by the Reporting Persons in the aggregate.

1	NAME OF REPORTING PERSON		
2	BVF Par CHECK TH APPROPRI BOX IF A MEMBER O GROUP	ATE (a) OF A	
		(b)	
3	SEC USE O	NLY	
4	CITIZENSI ORGANIZA	HIP OR PLACE OF ATION	
	Delawar	e	
NUMBER OF	5	SOLE VOTING POWER	
SHARES BENEFICIALLY	7	0 shares	
OWNED BY	6	SHARED VOTING POWER	
EACH REPORTING PERSON WITH	7	1,492,836 ⁽¹⁾ SOLE DISPOSITIVE	
TERSON WITH	/	POWER	
	8	0 shares SHARED DISPOSITIVE POWER	
9	BENEFICIA	1,492,836 ⁽¹⁾ TE AMOUNT ALLY OWNED BY ORTING PERSON	
10	1,492,83 CHECK BC THE AGGR AMOUNT 1 (9) EXCLU CERTAIN SHARES	OX IF REGATE IN ROW	

PERCENT OF CLASS
11 REPRESENTED BY AMOUNT
IN ROW (9)

9.99%(1)

12 TYPE OF REPORTING

PERSON

PN, IA

(1) Includes 772,006 shares of Common Stock currently issuable upon conversion of 772,006 shares of Series 1 Preferred. Excludes 2,095,994 shares of Common Stock underlying certain shares of Series 1 Preferred currently not convertible due to the Beneficial Ownership Limitation. As of the close of business on March 29, 2018, the Beneficial Ownership Limitation limits the aggregate conversion of Series 1 Preferred by the Reporting Persons to 772,006 out of the 2,868,000 shares of Common Stock underlying the Series 1 Preferred owned by the Reporting Persons in the aggregate.

1 NAME OF REPORTING PERSON

BVF Inc.

CHECK THE

APPROPRIATE

2 BOX IF A (a)
MEMBER OF
A GROUP

(b)

3 SEC USE ONLY

CITIZENSHIP OR PLACE OF

ORGANIZATION

Delaware

NUMBER 5 SOLE VOTING POWER

SHARES